Monitoring Arteriovenous Malformation Response to Genotype-Targeted Therapy
Arteriovenous malformations (AVMs) have recently been reported to have a high incidence of somatic KRAS mutations suggesting potential for treatment with mitogen-activated protein kinase inhibitors. In this case report, we describe genotype-targeted treatment of a KRAS mutant metameric AVM in a pati...
Gespeichert in:
| Veröffentlicht in: | Pediatrics (Evanston) 2020-09, Vol.146 (3), p.1 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 1 |
| container_title | Pediatrics (Evanston) |
| container_volume | 146 |
| creator | Edwards, Emily A. Phelps, Andrew S. Cooke, Daniel Frieden, Ilona J. Zapala, Matthew A. Fullerton, Heather J. Shimano, Kristin A. |
| description | Arteriovenous malformations (AVMs) have recently been reported to have a high incidence of somatic KRAS mutations suggesting potential for treatment with mitogen-activated protein kinase inhibitors. In this case report, we describe genotype-targeted treatment of a KRAS mutant metameric AVM in a patient with Cobb syndrome using the mitogen-activated protein kinase inhibitor trametinib. Therapeutic response was monitored with phase-contrast magnetic resonance angiography to quantify AVM arterial inflow as an imaging biomarker. Treatment with trametinib resulted in a substantial decrease in blood flow to the AVM, with a >75% reduction in arterial inflow after 6 months of trametinib therapy. |
| doi_str_mv | 10.1542/peds.2019-3206 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2438678443</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2438678443</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-1824919e300aa73ac16fc777cc4c8bd0172b6d0c8144794a9c9eb7594d6228673</originalsourceid><addsrcrecordid>eNpd0M9LwzAUwPEgCs4fV88FL14yX360aY5j6BQ3BJnnkKWvs6NrapIJ--9tmSdP7_A-PB5fQu4YTFku-WOPVZxyYJoKDsUZmTDQJZVc5edkAiAYlQD5JbmKcQcAMld8Qt5WvmuSD023zWYhYWj8D3b-ELOVbWsf9jY1vss-MPa-i5glny2GfTr2SNc2bDFhla2_MNj-eEMuattGvP2b1-Tz-Wk9f6HL98XrfLakTkhIlJVcaqZRAFirhHWsqJ1Syjnpyk0FTPFNUYErmZRKS6udxo3KtawKzstCiWvycLrbB_99wJjMvokO29Z2OHxuuBQDK6UUA73_R3f-ELrhu0FJzUsAXgxqelIu-BgD1qYPzd6Go2FgxrZmbGvGtmZsK34BjPpsdA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2449280026</pqid></control><display><type>article</type><title>Monitoring Arteriovenous Malformation Response to Genotype-Targeted Therapy</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Edwards, Emily A. ; Phelps, Andrew S. ; Cooke, Daniel ; Frieden, Ilona J. ; Zapala, Matthew A. ; Fullerton, Heather J. ; Shimano, Kristin A.</creator><creatorcontrib>Edwards, Emily A. ; Phelps, Andrew S. ; Cooke, Daniel ; Frieden, Ilona J. ; Zapala, Matthew A. ; Fullerton, Heather J. ; Shimano, Kristin A.</creatorcontrib><description>Arteriovenous malformations (AVMs) have recently been reported to have a high incidence of somatic KRAS mutations suggesting potential for treatment with mitogen-activated protein kinase inhibitors. In this case report, we describe genotype-targeted treatment of a KRAS mutant metameric AVM in a patient with Cobb syndrome using the mitogen-activated protein kinase inhibitor trametinib. Therapeutic response was monitored with phase-contrast magnetic resonance angiography to quantify AVM arterial inflow as an imaging biomarker. Treatment with trametinib resulted in a substantial decrease in blood flow to the AVM, with a >75% reduction in arterial inflow after 6 months of trametinib therapy.</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.2019-3206</identifier><language>eng</language><publisher>Evanston: American Academy of Pediatrics</publisher><subject>Angiography ; Blood flow ; Enzyme inhibitors ; Genotypes ; K-Ras protein ; Kinases ; MAP kinase ; Pediatrics ; Protein kinase inhibitors</subject><ispartof>Pediatrics (Evanston), 2020-09, Vol.146 (3), p.1</ispartof><rights>Copyright American Academy of Pediatrics Sep 1, 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c340t-1824919e300aa73ac16fc777cc4c8bd0172b6d0c8144794a9c9eb7594d6228673</citedby><cites>FETCH-LOGICAL-c340t-1824919e300aa73ac16fc777cc4c8bd0172b6d0c8144794a9c9eb7594d6228673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids></links><search><creatorcontrib>Edwards, Emily A.</creatorcontrib><creatorcontrib>Phelps, Andrew S.</creatorcontrib><creatorcontrib>Cooke, Daniel</creatorcontrib><creatorcontrib>Frieden, Ilona J.</creatorcontrib><creatorcontrib>Zapala, Matthew A.</creatorcontrib><creatorcontrib>Fullerton, Heather J.</creatorcontrib><creatorcontrib>Shimano, Kristin A.</creatorcontrib><title>Monitoring Arteriovenous Malformation Response to Genotype-Targeted Therapy</title><title>Pediatrics (Evanston)</title><description>Arteriovenous malformations (AVMs) have recently been reported to have a high incidence of somatic KRAS mutations suggesting potential for treatment with mitogen-activated protein kinase inhibitors. In this case report, we describe genotype-targeted treatment of a KRAS mutant metameric AVM in a patient with Cobb syndrome using the mitogen-activated protein kinase inhibitor trametinib. Therapeutic response was monitored with phase-contrast magnetic resonance angiography to quantify AVM arterial inflow as an imaging biomarker. Treatment with trametinib resulted in a substantial decrease in blood flow to the AVM, with a >75% reduction in arterial inflow after 6 months of trametinib therapy.</description><subject>Angiography</subject><subject>Blood flow</subject><subject>Enzyme inhibitors</subject><subject>Genotypes</subject><subject>K-Ras protein</subject><subject>Kinases</subject><subject>MAP kinase</subject><subject>Pediatrics</subject><subject>Protein kinase inhibitors</subject><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpd0M9LwzAUwPEgCs4fV88FL14yX360aY5j6BQ3BJnnkKWvs6NrapIJ--9tmSdP7_A-PB5fQu4YTFku-WOPVZxyYJoKDsUZmTDQJZVc5edkAiAYlQD5JbmKcQcAMld8Qt5WvmuSD023zWYhYWj8D3b-ELOVbWsf9jY1vss-MPa-i5glny2GfTr2SNc2bDFhla2_MNj-eEMuattGvP2b1-Tz-Wk9f6HL98XrfLakTkhIlJVcaqZRAFirhHWsqJ1Syjnpyk0FTPFNUYErmZRKS6udxo3KtawKzstCiWvycLrbB_99wJjMvokO29Z2OHxuuBQDK6UUA73_R3f-ELrhu0FJzUsAXgxqelIu-BgD1qYPzd6Go2FgxrZmbGvGtmZsK34BjPpsdA</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Edwards, Emily A.</creator><creator>Phelps, Andrew S.</creator><creator>Cooke, Daniel</creator><creator>Frieden, Ilona J.</creator><creator>Zapala, Matthew A.</creator><creator>Fullerton, Heather J.</creator><creator>Shimano, Kristin A.</creator><general>American Academy of Pediatrics</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>20200901</creationdate><title>Monitoring Arteriovenous Malformation Response to Genotype-Targeted Therapy</title><author>Edwards, Emily A. ; Phelps, Andrew S. ; Cooke, Daniel ; Frieden, Ilona J. ; Zapala, Matthew A. ; Fullerton, Heather J. ; Shimano, Kristin A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-1824919e300aa73ac16fc777cc4c8bd0172b6d0c8144794a9c9eb7594d6228673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Angiography</topic><topic>Blood flow</topic><topic>Enzyme inhibitors</topic><topic>Genotypes</topic><topic>K-Ras protein</topic><topic>Kinases</topic><topic>MAP kinase</topic><topic>Pediatrics</topic><topic>Protein kinase inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Edwards, Emily A.</creatorcontrib><creatorcontrib>Phelps, Andrew S.</creatorcontrib><creatorcontrib>Cooke, Daniel</creatorcontrib><creatorcontrib>Frieden, Ilona J.</creatorcontrib><creatorcontrib>Zapala, Matthew A.</creatorcontrib><creatorcontrib>Fullerton, Heather J.</creatorcontrib><creatorcontrib>Shimano, Kristin A.</creatorcontrib><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Edwards, Emily A.</au><au>Phelps, Andrew S.</au><au>Cooke, Daniel</au><au>Frieden, Ilona J.</au><au>Zapala, Matthew A.</au><au>Fullerton, Heather J.</au><au>Shimano, Kristin A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Monitoring Arteriovenous Malformation Response to Genotype-Targeted Therapy</atitle><jtitle>Pediatrics (Evanston)</jtitle><date>2020-09-01</date><risdate>2020</risdate><volume>146</volume><issue>3</issue><spage>1</spage><pages>1-</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><abstract>Arteriovenous malformations (AVMs) have recently been reported to have a high incidence of somatic KRAS mutations suggesting potential for treatment with mitogen-activated protein kinase inhibitors. In this case report, we describe genotype-targeted treatment of a KRAS mutant metameric AVM in a patient with Cobb syndrome using the mitogen-activated protein kinase inhibitor trametinib. Therapeutic response was monitored with phase-contrast magnetic resonance angiography to quantify AVM arterial inflow as an imaging biomarker. Treatment with trametinib resulted in a substantial decrease in blood flow to the AVM, with a >75% reduction in arterial inflow after 6 months of trametinib therapy.</abstract><cop>Evanston</cop><pub>American Academy of Pediatrics</pub><doi>10.1542/peds.2019-3206</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-4005 |
| ispartof | Pediatrics (Evanston), 2020-09, Vol.146 (3), p.1 |
| issn | 0031-4005 1098-4275 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2438678443 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Angiography Blood flow Enzyme inhibitors Genotypes K-Ras protein Kinases MAP kinase Pediatrics Protein kinase inhibitors |
| title | Monitoring Arteriovenous Malformation Response to Genotype-Targeted Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T06%3A30%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Monitoring%20Arteriovenous%20Malformation%20Response%20to%20Genotype-Targeted%20Therapy&rft.jtitle=Pediatrics%20(Evanston)&rft.au=Edwards,%20Emily%20A.&rft.date=2020-09-01&rft.volume=146&rft.issue=3&rft.spage=1&rft.pages=1-&rft.issn=0031-4005&rft.eissn=1098-4275&rft_id=info:doi/10.1542/peds.2019-3206&rft_dat=%3Cproquest_cross%3E2438678443%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2449280026&rft_id=info:pmid/&rfr_iscdi=true |